inagliptin study of effects on PPG,postprandial blood glucose control
- Conditions
- Type 2 Diabetes
- Registration Number
- JPRN-UMIN000008591
- Lead Sponsor
- Japan society of Patient Reported Outcome
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 380
Not provided
1.Type I and secondary diabetes 2.Severe infectious disease, before or after surgery, and severe trauma 3.Events of myocardial infarction, angina pectoris, cerebral stroke, and cerebral infarction 4.Severe liver dysfunction (AST: 100 IU/l or higher) 5.Moderate or severer heart failure, (NYHA/New York Heart Association stage III or severer) 6.Under treatment with diabetic drugs at the time of study initiation 7.Pregnant, lactating, and possibly pregnant women and those planning to become pregnant 8.Past medical history of hypersensitivity to investigational drugs 9.Patients with cancer 10.Patent receiving steroid therapy with inflammatory affection 11.Past medical history of abdominal operation and ileus 12.Judged as ineligible by clinical investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A dietary tolerance test with a test meal will be conducted. Major evaluation items include the fasting blood glucose level early in the morning, its levels 2 hours after meals, and HbA1c at the start of administration (Week 0) and after 12 weeks.
- Secondary Outcome Measures
Name Time Method